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Abstract Catalytic asymmetric formal synthesis of (-)-Triptophenolide and (?)-Triptolide have been achieved. Key
reaction involves Palladium catalyzed asymmetric conjugate addition of aryl boronic acid to 3-methyl cyclohexe-1-none to
form quaternary carbon. Claisen rearrangement and subsequent aldol reaction furnished trans-decaline key intermediate,
which assured a formal total synthesis of (-)-Triptophenolide and (?)-Triptolide.
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1 Introduction
Tripterygium wilfordii Hook F has long been used to treat
rheumatoid arthritis in southern China. The active com-
ponent was first determined to be Triptolide (TP) (Fig. 1)
after it was isolated by Kupchan in 1972 [1]. The unique
tri-epoxide moiety attracted numerous attention to identify
its molecular mechanism of action in cancer [2–8],
immunosuppression [9–11] and contraception [12]. Trip-
tophenolide, a precursor of TP, exhibited potent anti
inflammatory and immunosuppressive activity [13, 14].
By using TP as tool molecule, biological researches
have accumulated a lot of discoveries which keep TP as a
hot topic. These findings have, in return, promoted the
development of efficient synthesis strategy. We seek to
discover new lead compounds, especially from nature ter-
penoids, for the development of anticancer drug [15–17].
Hence, TP is a valuable target for us to investigate SAR of
tri-epoxide. We initiated this research in order to develop a
catalytic asymmetric synthetic route because it has not
been achieved.
Reports of its total synthesis were available from 1980,
[18, 19] and the maximum productivity was reached
around 2000 [20–23]. So far, only two stereoselective
synthesis were reported, and both used chiral auxiliaries
[22, 24]. On the other hand, in 2008, Sherburn reported an
elegant synthesis with a Diels–Alder reaction [25]. Only
preliminary enantioselective synthesis of vinyl iodide was
performed and we regard it as a racemic synthesis and will
report the first catalytic asymmetric formal total synthesis
of (-)-Triptophenolide and (?)-TP, which features a pal-
ladium catalyzed conjugate addition of arylboronic acid to
cyclic enone to construct all-carbon quaternary stereocen-
ter, followed by new cyclization strategy involving claisen
rearrangement [26] and aldol reaction.
The retrosynthetic analysis is depicted in Scheme 1.
Unlike precedent methods including biogenetic cascade
radical [21, 27] or cationic [28–30] cyclization and alky-
lation of benzocyclohexanone derivatives, [18, 24] or
Diels–Alder reaction [25] to construct the quaternary cen-
ter, we envisioned that it could be formed enantioselec-
tively via arylboronic acid addition to cyclic enone, a
methodology pioneered by Prof. Lu [31] and developed by
Prof. Stoltz [32–34].
As illustrated in scheme 1, TP and triptophenolide could
be synthesized from tetracycle 3, [28] the butenolide
installation could be accomplished from key intermediate
tricyclic ketone 4,1 [35–38] which is accessible by a 3-step
transformation including Claisen rearrangement, alkene
oxidation and aldol cyclization. Trans-cyclization could be
realized if dehydration occurs at C6-C7 after diasterose-
lective aldol reaction. The quaternary stereocenter in 6
could be constructed by above mentioned coupling
reaction.
2 Results and Discussion
Our synthesis commenced with coupling reaction of aryl-
boronic acid 8 [15]. Commercially available 3-Me-cyclo-
hexenone was treated with trifluoroacetic palladium and
(s)-t-BuPyOX ligand in heterogeneous solvent and 9 was
isolated in moderate ee and 73 % yield [32]. The absolute
configuration was determined accordingly [32]. Removal
of Benzyl group by hydrogenation and allylation with allyl
bromide afforded 6 as precursor of Claisen rearrangement.
Treatment of 6 under microwave irradiation for 40 min
gave rise to anticipated allyl phenol 11 as a minor product,
together with tricyclic phenol 13 which was a product of
Conia-ene reaction starting from 11 (Scheme 2). Unfortu-
nately, attempts were failed to improve the yield of 11 by
controlling reaction time and temperature. Alternative
strategy need to be adopted to avoid side reactions.
As illustrated in Scheme 2, tautomerization of ketone
into enol was the reason of side reaction. Consequently,
prevention of the tautomerization by reduction of ketone












































Scheme 1 Retrosynthetic analysis of 1 and 2
1 See representative references for catalytic asymmetric construction
of 6,6,6-tricycles.
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thermo condition, ortho-claisen rearrangement of 14
afforded diol 15 in 71 % yield (Scheme 3). Routine methyl
protection of phenol and subsequent PCC oxidation pro-
duced ketone 5 in 87 % yield in 2 steps.
RuCl3 oxidation of terminal alkene 5 to corresponding
aldehyde 17 (75 % yield) set up the stage for diastereose-
lective aldol reaction (Scheme 4). Both isomers were iso-
lated and trans-isomer was determined by NMR spectrum
analysis. We were delightful that dehydration (C6-C7)
proceeded in situ to give a thermodynamically stable aro-
matic alkene 19 in 51 % isolated yield (dehydration at C5-
C6 was also possible, however, we did not detect such
intermediate by TLC monitor at rt or higher temperature).
TLC analysis showed that cis-isomer 18 diminished when
reaction temperature was elevated. Hence, acceptable yield
was obtained by adding p-TsOH at higher temperature.
This provides a method to build cis backbone of 6-6-6
structure which is difficult to access by acidic cyclization
[39]. However, after screening of different acids (Cam-
phorsulfonic acid, TiCl4, BF3OEt2, Proline) and bases
(KOH, K2CO3, KO-t-Bu), no further improvement was
realized to produce more trans isomer. Hydrogenation of
19 furnished key intermediate 4 in 93 % yield and the ee
value of 4 was determined to be 83 %. The spectra of 4
were identical with reported data [28–30]. From 4, (?)-TP
and (-)-Triptophenolide could be synthesized with repor-
ted methods [28].
In summary, the first catalytic asymmetric formal total
synthesis of (?)-Triptolide and (-)-Triptophenolide have
been accomplished in 10 steps with 13 % yield. Key reac-
tions involve a catalytic asymmetric construction of qua-
ternary stereocenter and subsequent ring close via Claisen
rearrangement, aldol reaction. This work demonstrated a
new strategy for asymmetric construction of tricyclic ketone
like 4. Further researches on this application in total syn-
thesis of bioactive natural products are ongoing in our lab.
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Scheme 4 Aldol cyclization
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